用抗细胞间粘附分子1单克隆抗体治疗难治性类风湿关节炎。
Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1.
作者信息
Kavanaugh A F, Davis L S, Nichols L A, Norris S H, Rothlein R, Scharschmidt L A, Lipsky P E
机构信息
University of Texas Southwestern Medical Center, Dallas 75235-8884.
出版信息
Arthritis Rheum. 1994 Jul;37(7):992-9. doi: 10.1002/art.1780370703.
OBJECTIVE
To assess the safety and efficacy of a monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in rheumatoid arthritis (RA).
METHODS
A phase I/II, open-label, dose-escalation study of 32 patients.
RESULTS
During treatment, a peripheral CD3+/CD4+ lymphocytosis was noted, and several patients demonstrated transient cutaneous anergy, which suggests that therapy modified T cell recirculation. Thirteen of the 23 patients who received 5 days of treatment demonstrated clinical improvement through day 29, and 9 of 23 through day 60. Adverse effects were minor and transient.
CONCLUSION
Anti-ICAM-1 MAb therapy was well tolerated, resulted in a transient alteration in T lymphocyte recirculation, and effected clinical improvement in some RA patients.
目的
评估一种针对细胞间黏附分子1（ICAM-1；CD54）的单克隆抗体（MAb）在类风湿关节炎（RA）中的安全性和疗效。
方法
一项针对32例患者的I/II期开放标签剂量递增研究。
结果
治疗期间，观察到外周血CD3+/CD4+淋巴细胞增多，部分患者出现短暂性皮肤无反应性，这表明治疗改变了T细胞再循环。在接受5天治疗的23例患者中，13例在第29天出现临床改善，23例中有9例在第60天出现临床改善。不良反应轻微且短暂。
结论
抗ICAM-1单克隆抗体治疗耐受性良好，导致T淋巴细胞再循环出现短暂改变，并使部分类风湿关节炎患者的临床症状得到改善。
Zotero 插件